一心堂药业集团股份有限公司 关于选举第七届董事会职工代表董事的公告 一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-118 号 2025 年 11 月 13 日 第 1 页 共 2 页 一心为民 全心服务 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）第六届董事会任期即将届满，根据《中 华人民共和国公司法》《公司章程》等法律、法规、规范性文件的有关规定，公司于2025年11 月12日召开了职工代表大会，经与会职工代表民主选举，同意选举郭春丽女士（简历详见附件） 为第七届董事会职工代表董事，郭春丽女士将与公司2025年度第三次临时股东会选举产生的5 名非独立董事和3名独立董事共同组成公司第七届董事会，其任职自职工代表大会选举通过之日 起生效，职工代表董事任期与第七届董事会任期一致,任期三年(自2025年11月17日公司第六届 董事会任期届满之日起三年)。 上述职工代表董事符合《公司法》《公司章程》等关于董事任职的资格和条件，其将按照 有关法规行使董事职权。本次选举完成后，公司董事会 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-117 号 一心堂药业集团股份有限公司 2025 年度第三次临时股东会暨中小投资者表决结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有增加、否决或变更提案。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025 年 11 月 13 日（星期四）下午 14 点。 （2）网络投票时间：2025 年 11 月 13 日。其中，通过深圳证券交易所交易系统进行网络 投票的具体时间为 2025 年 11 月 13 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 11 月 13 日上午 9:15 至下午 15:00 的任意时间。 2.召开地点：一心堂药业集团股份有限公司会议室 3.召开方式：现场投票及网络投票 4.召集人：本公司董事会 5.主持人：董事长阮鸿献先生。 6.会议通知 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 2025 年度第三次临时股东会的法律意见书 致：一心堂药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证券监 督管理委员会颁布的《上市公司股东会规则（2025年修订）》（以下简称"《股 东会规则》"）的规定，北京市竞天公诚律师事务所（以下简称"本所"）指派律 师对一心堂药业集团股份有限公司（以下简称"公司"）2025年度第三次临时股东 会（以下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜出具本 法律意见书。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法（2023）》和《律师事务所证券法律业务执业规则（试行）》等规 定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所 认定的事实真实、准确、完整，所发表的结 ...

Core Viewpoint - YXTT Pharmaceutical Group Co., Ltd. has announced the implementation of a cash management plan utilizing up to 2.5 billion yuan of idle funds to enhance the efficiency of fund usage [1][2]. Group 1: Cash Management Plan - The company approved a cash management plan at the 2024 annual shareholders' meeting on May 21, 2025, allowing the use of up to 2.5 billion yuan of idle funds for investments in fixed-income or capital-preserving floating-return financial products, large certificates of deposit, and time deposits [2]. - The collaboration with Huaxia Bank is a recent step in this cash management initiative, although specific investment amounts and product details were not disclosed [2]. Group 2: Risk Control and Investment Strategy - YXTT emphasizes a low-risk investment strategy, adhering to principles of "standardized operation, risk prevention, and cautious investment" [3]. - The company has established a multi-layered risk control mechanism, including oversight by the financial department, internal audits, and regular checks by independent directors to ensure the safety of funds [3]. Group 3: Normalization of Fund Management - Utilizing idle funds for cash management has become a regular practice for YXTT, reflecting its flexibility and standardization in fund management [4]. - The board believes that low-risk financial management can enhance the overall performance of the company while safeguarding fund security, aligning with the interests of all shareholders [4].

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-115 号 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司与华夏银行股份有限公司昆明红塔支行签订了《华夏银行人民币单位结构性存 款业务协议》，本次进行现金管理基本情况如下： 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 | 签约银行 | ...

一心为民 全心服务 关于全资子公司广西鸿翔一心堂药业有限责任公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为全资子公司广西鸿翔一心堂药业 有限责任公司（以下简称"广西一心堂"或"债务人")提供连带责任保证方式的担保，被担保 企业广西一心堂最近一期经审计（2024年12月31日）的资产负债率超过70%，敬请投资者充分关 注担保风险。 股票代码：002727 股票简称：一心堂 公告编号：2025-116 号 一心堂药业集团股份有限公司 一、担保情况概述 公司于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同意子公 司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向相关银 行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元的金额 上限内以银行授信为准，以上综合授信的金额在一年内以银行授信为准。《关于同意子公司向 相关银行申请综合授信额度并为其提供担保的 ...

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and disinfectants 6.55% [1][2]. Stock Performance - As of November 12, Yixintang's stock price increased by 2.02%, reaching 14.14 CNY per share, with a market capitalization of 8.28 billion CNY. The stock has risen 12.85% year-to-date, with a 5.52% increase over the last five trading days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on May 23, where it recorded a net buy of -4.0951 million CNY [1]. Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2][3]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per shareholder decreased by 9.53% to 10,596 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.3144 million shares, an increase of 3.74 million shares from the previous period. Several new institutional shareholders have entered the top ten list [3]. Dividend Distribution - Since its A-share listing, Yixintang has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the past three years [3].

一心为民 全心服务 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司与华夏银行股份有限公司昆明红塔支行签订了《华夏银行人民币单位结构性存 款业务协议》，本次进行现金管理基本情况如下： | 签约银行 | 产品名称 | 认购金额 | 收益类型 | 合同起始日 | 合同到期日 | 产品预期收 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | （万元） | | | | 益率（年） | | 华夏银行 ...

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and sanitary products 6.55% [1]. Stock Performance - As of November 10, Yixintang's stock price increased by 2.14%, reaching 13.83 CNY per share, with a trading volume of 1.04 billion CNY and a turnover rate of 1.92%. The total market capitalization is 80.99 billion CNY [1]. - Year-to-date, Yixintang's stock price has risen by 10.38%, with a 3.44% increase over the last five trading days, a 0.66% increase over the last 20 days, and a 6.01% decrease over the last 60 days [1]. Financial Performance - For the period from January to September 2025, Yixintang reported operating revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 shares per shareholder, a decrease of 9.53% [2]. - The company has distributed a total of 2.023 billion CNY in dividends since its A-share listing, with 764 million CNY distributed in the last three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 22.3144 million shares, an increase of 3.74 million shares from the previous period. New institutional shareholders include several funds, such as Xingquan Trend Investment Mixed Fund and Rongtong Health Industry Flexible Allocation Mixed Fund [3].

Core Viewpoint - Yunnan's "Medicine King" Ruan Hongxian is in the spotlight following Yixin Hall's announcement of a share transfer to his daughters, amidst the company's ongoing performance decline and strategic transformation efforts [1][10]. Company Overview - Yixin Hall, founded by Ruan Hongxian, has grown to operate 11,372 pharmacies, establishing itself as a leading player in the southwestern Chinese pharmaceutical retail market [1][9]. - The company reported a revenue decline of 4.33% year-on-year to 13 billion yuan and a net profit drop of 8.17% to 269 million yuan for the first three quarters of 2025 [1]. Historical Background - Ruan Hongxian began his career in the pharmaceutical industry at the age of 14, eventually founding Yixin Hall in 2006 after years of building a reputation for quality [3][4]. - The company went public in 2014, marking a significant milestone in its expansion journey, with revenues reaching 17.43 billion yuan and net profits hitting 1.01 billion yuan by 2022 [4]. Strategic Challenges and Responses - The company has faced challenges such as declining gross margins due to policy changes and market competition, prompting Ruan to initiate a strategic transformation [7][8]. - A dual-track transformation strategy has been proposed, with plans to convert 70% of stores to multi-category health stores and 30% to professional pharmacies, enhancing the medical attributes of nearly one-third of the stores [8][9]. Family Succession and Future Outlook - Ruan Hongxian is transferring shares to his daughters as part of a family wealth succession plan, with the total value of the shares amounting to approximately 157 million yuan [1][10]. - The involvement of the next generation, particularly Ruan Aixiang as vice president, is seen as crucial for the company's innovative development amid ongoing transformation efforts [2][11].